首站-论文投稿智能助手
典型文献
Recent research and development of DYRK1A inhibitors
文献摘要:
Dual specificity tyrosine phosphorylation regulated kinase 1A(DYRK1A)is an evolutionarily conserved protein kinase belonging to the CMGC kinase family,which is closely related to Down syndrome(DS)and Alzheimer's disease(AD).In recent years,not only the treatment of diabetes,but also the treatment of cancer gradually focuses on targeting DYRK1A.Therefore,a series of DYRK1A inhibitors have been developed to treat relevant diseases and clarify their treatment mechanism furtherly.DYRK1A inhibitors are mainly divided into natural products and synthetic compounds.Among them,harmine is an excellent DYRK1A inhibitor.Therefore,the synthetic DYRK1A inhibitors are mainly based on harmine,which greatly enriches the structure and quantity of DYRK1A inhibitors.The interaction between the inhibitors and the DYRK1A protein has a guiding significance in predicting the activity of the inhibitors,and plays an irreplaceable role in the design of the compounds.This paper mainly reviews DYRK1A inhibitors found in recent years and their structure-activity relationship,looking forward to providing a theoretical basis for the development of DYRK1A inhibitors.
文献关键词:
作者姓名:
Liyun Zhao;Xuan Xiong;Li Liu;Qi Liang;Rongsheng Tong;Xuanlin Feng;Lan Bai;Jianyou Shi
作者机构:
Personalized Drug Therapy Key Laboratory of Sichuan Province,Sichuan Academy of Medical Science&Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,China;College of Medicine,Southwest Jiaotong University,Chengdu 610031,China;Emergency Intensive Care Unit,Personalized Drug Therapy Key Laboratory of Sichuan Province,Sichuan Academy of Medical Science&Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610072,China
引用格式:
[1]Liyun Zhao;Xuan Xiong;Li Liu;Qi Liang;Rongsheng Tong;Xuanlin Feng;Lan Bai;Jianyou Shi-.Recent research and development of DYRK1A inhibitors)[J].中国化学快报(英文版),2022(04):1841-1849
A类:
CMGC
B类:
Recent,research,development,DYRK1A,inhibitors,Dual,specificity,tyrosine,phosphorylation,regulated,kinase,evolutionarily,conserved,protein,belonging,family,which,closely,related,Down,syndrome,DS,Alzheimer,AD,In,recent,years,not,only,treatment,diabetes,but,also,cancer,gradually,focuses,targeting,Therefore,series,have,been,developed,relevant,diseases,clarify,their,mechanism,furtherly,are,mainly,divided,into,natural,products,synthetic,compounds,Among,them,harmine,excellent,greatly,enriches,structure,quantity,interaction,between,has,guiding,significance,predicting,activity,plays,irreplaceable,role,design,This,paper,reviews,found,relationship,looking,forward,providing,theoretical,basis
AB值:
0.53915
相似文献
Long-term exposure to genistein inhibits the proliferation of gallbladder cancer by downregulating the MCM complex
Yajun Geng;Shili Chen;Yang Yang;Huijie Miao;Xuechuan Li;Guoqiang Li;Jian Ma;Tong Zhang;Tai Ren;Yongsheng Li;Lin Li;Liguo Liu;Jiahua Yang;Ziyi Wang;Lu Zou;Ke Liu;Yang Li;Siyuan Yan;Xuya Cui;Xuheng Sun;Bo Yang;Lingxiao Zhang;Xusheng Han;Chuanlei Wang;Bo Chen;Xueliang Yue;Wei Liang;Jianjun Ren;Jianguang Jia;Jianfeng Gu;Zhizhen Li;Tiansuo Zhao;Peng Wang;Dong Wei;Shimei Qiu;Dongxi Xiang;Xinsen Xu;Wei Chen;Min He;Linhua Yang;Hui Wang;Tao Chen;Rong Hua;Xu'an Wang;Xiangsong Wu;Wei Gong;Guangyi Wang;Maolan Li;Wei Zhang;Rong Shao;Wenguang Wu;Yingbin Liu-Department of Biliary-Pancreatic Surgery,Ren Ji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China;Department of General Surgery,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China;Shanghai Key Laboratory of Biliary Tract Disease Research,Shanghai 200127,China;Department of Hepatobiliary Surgery,Affiliated Hospital of Jining Medical University,Jining 272129,China;Department of General Surgery,The Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China;Department of Hepatobiliary and Pancreatic Surgery,The First Hospital of Jilin University,Changchun 130021,China;Department of Hepatobiliary and Pancreatic Surgery,Henan Provincial People's Hospital,Zhengzhou 450003,China;Department of Surgical Oncology,First Affiliated Hospital of Bengbu Medical College,Bengbu 233099,China;Department of General Surgery,Changshu No.1 People's Hospital Affiliated to Soochow University,Changshu 215500,China;Department of Biliary Surgery,Eastern Hepatobiliary Surgery Hospital,Shanghai 200433,China;Department of Pancreatic Cancer,Tianjin Medical University Cancer Institute and Hospital,Tianjin 300060,China;Department of Hepatobiliary Surgery,Affiliated Hospital of Nantong University,Nantong 226001,China;State Key Laboratory of Oncogene and Related Genes and Department of Epidemiology,Shanghai Cancer Institute,Shanghai 200127,China;Department of Pharmacology,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;State Key Laboratory of Oncogenes and Related Genes,Shanghai Cancer Institute,Shanghai 200127,China
Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy
Xin Sun;Yuhan Shu;Guiqin Ye;Caixia Wu;Mengting Xu;Ruilan Gao;Dongsheng Huang;Jianbin Zhang-Department of Oncology,Cancer Center of Zhejiang Provincial People's Hospital,Affiliated People's Hospital,Hangzhou Medical College,Hangzhou 310014,China;College of Biomedical Engineering&Instrument Science,Zhejiang University,Hangzhou 310028,China;Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province,Hangzhou Medical College,Hangzhou 310014,China;Clinical Research Institute,Zhejiang Provincial People,s Hospital,Affiliated People,s Hospital,Hangzhou Medical College,Hangzhou 310014,China;Department of Hematology,the First Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou 310006,China
Novel dual inhibitor for targeting PIM1 and FGFR1 kinases inhibits colorectal cancer growth in vitro and patient-derived xenografts in vivo
Fanxiang Yin;Ran Zhao;Dhilli Rao Gorja;Xiaorong Fu;Ning Lu;Hai Huang;Beibei Xu;Hanyong Chen;Jung-Hyun Shim;Kangdong Liu;Zhi Li;Kyle Vaughn Laster;Zigang Dong;Mee-Hyun Lee-Department of Pathophysiology,School of Basic Medical Sciences,Zhengzhou University,Zhengzhou 450001,China;China-US(Henan)Hormel Cancer Institute,Zhengzhou 450008,China;Translational Medical Center,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;The Hormel Institute,University of Minnesota,Austin,MN 55912,USA;Department of Biomedicine,Health&Life Convergencen Science,BK21 Four,College of Pharmacy,Mokpo National University,Jeonnam 58554,Republic of Korea;The Collaborative Innovation Center of Henan Province for Cancer Chemoprevention,Zhengzhou 450001,China;Department of General Surgery,the Affiliated Tumor Hospital of Zhengzhou University,Zhengzhou 450008,China;College of Korean Medicine,Dongshin University,Naju 58245,Republic of Korea
Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19
Yang Yi;Meng Zhang;Heng Xue;Rong Yu;Yang-Oujie Bao;Yi Kuang;Yue Chai;Wen Ma;Jing Wang;Xiaomeng Shi;Wenzhe Li;Wei Hong;Junhua Li;Elishiba Muturi;Hongping Wei;Joachim Wlodarz;Szczepan Roszak;Xue Qiao;Hang Yang;Min Ye-State Key Laboratory of Natural and Biomimetic Drugs,School of Pharmaceutical Sciences,Peking University,Beijing 100191,China;CAS Key Laboratory of Special Pathogens and Biosafety,Center for Biosafety Mega-Science,Wuhan Institute of Virology,Chinese Academy of Sciences,Wuhan 430071,China;University of Chinese Academy of Sciences,Beijing 100049,China;Faculty of Science and Technology,University of Silesia,Katowice 40-007,Poland;Department of Physical and Quantum Chemistry,Faculty of Chemistry,Wroclaw University of Science and Technology,Wroclaw 50-370,Poland
Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
Chengliang Sun;Yao Cheng;Xiaojia Liu;Gefei Wang;Wenjian Min;Xiao Wang;Kai Yuan;Yi Hou;Jiaxing Li;Haolin Zhang;Haojie Dong;Liping Wang;Chenguang Lou;Yanze Sun;Xinmiao Yu;Hongbin Deng;Yibei Xiao;Peng Yang-State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization,China Pharmaceutical University,Nanjing 210009,China;Department of Medicinal Chemistry,School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China;Department of Pharmacology,School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China;Beijing Institute of Clinical Pharmacy,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China;Department of Physics,Chemistry and Pharmacy,University of Southern Denmark,Campusvej 55,5230 Odense,Denmark;Institute of Medicinal Biotechnology,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。